The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Open accessAbstract
Drug With a (Re)Purpose: Thalidomide, once infamous for its deleterious effects on fetal development, has re-emerged as a drug of great interest because of its beneficial immunomodulatory effects. A derivative drug called lenalidomide significantly extends the survival of patients with multiple myeloma, but the molecular mechanisms underlying its efficacy remain unclear (see the Perspective by Stewart ). Building on a previous observation that thalidomide binds to cereblon, a ubiquitin ligase, Lu et al. (p. 305 , published online 28 November) and Krönke et al. (p. 301 , published online 28 November) show that in the presence of lenalidomide, cereblon selectively targets two B cell transcription factors (Ikaros family members, IKZF1 and IKZF3) for degradation. In myeloma cell lines and patient cells, down-regulation of IKZF1 and IKZF3 was necessary and sufficient for the drug's anticancer activity. Thus, lenalidomide may act, at least in part, by “grepurposing” a ubiquitin ligase.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thalidomide analogues recruit zinc-finger transcription factors and other targets to CRBN8–11, the substrate receptor of the cullin-RING E3 ubiquitin ligase CUL4A/B-RBX1-DDB1-CRBN (CRL4CRBN)12.”
From The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K (2020) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The small molecules thalidomide, lenalidomide, and pomalidomide induce the ubiquitination and proteasomal degradation of the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3) by recruiting a Cys2-His2 (C2H2) zinc finger domain to Cereblon (CRBN), the substrate receptor of the CRL4CRBN E3 ubiquitin ligase.”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thalidomide analogs bind Cereblon (CRBN), the substrate receptor of the CUL4-RBX1-DDB1-CRBN (CRL4CRBN) E3 ubiquitin ligase and alter its substrate selectivity to recruit, ubiquitinate and degrade seemingly unrelated proteins including Ikaros (IKZF1), Aiolos (IKZF3), Casein kinase 1 alpha (CK1α) and GSPT1 (2–7).”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“proteome-wide mass-spectrometry demonstrated selective degradation of endogenous IKZF1/3, and ZFP91 in multiple cell lines (3, 4, 16).”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thalidomide, lenalidomide and pomalidomide mediate CRL4CRBN-dependent degradation of a larger number of proteins than previously appreciated through a C2H2 ZF degron (3, 4, 16).”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [3]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“their recruitment to cRl4 cRBN , upon lenalidomide treatment, led to their selective ubiquitylation and proteasomal degradation, ablating their role at promoters of their target genes (Krönke et al. 2014;lu et al. 2014).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Krönke et al. 2014
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both thalidomide and lenalidomide lack specificity for iKZF2 (Krönke et al. 2014;lu et al. 2014), as it encodes a histidine in a critical thalidomidebinding position.”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Krönke et al. 2014
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mechanistic studies later confirmed that the efficacy of lenalidomide in 5q-MDS was actually due to the recruitment of an unexpected neo-substrate: the kinase cK1α (CSNK1A1) which resides within the long arm of chromosome 5 (5q32) (Krönke et al. 2014) (Figure 5B, i).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Krönke et al. 2014
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“IMiDs bind to cereblon and activate cereblon E3 ligase activity, resulting in the rapid ubiquitination and degradation of two specific B cell transcription factors, Ikaros family zinc finger proteins Ikaros (IKZF 1) and Aiolos (IKZF3).77–79”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [78]
The cited source says what the claim attributes to it.
In the citing paper
“lenalidomide was shown to promote the interaction between cRBN and two members of the ikaros transcription factor family: iKZF1 and iKZF3 (gandhi et al. 2014;Krönke et al. 2014;lu et al. 2014).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Krönke et al. 2014
The cited source says what the claim attributes to it.
In the citing paper
“As such, lenalidomide can promote the interaction between cRl4 cRBN and both iKZF1 and iKZF3 resulting in their selective degradation which disrupts their role at gene promoters (Krönke et al. 2014;lu et al. 2014).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Krönke et al. 2014
In the citing paper
“These compounds, collectively known as immunomodulatory drugs (IMiDs), can promote the degradation of a host of cellular proteins by extending the subpar interfaces they form with CRBN, the substrate receptor of the CUL4-RBX1-DDB1 (CRL4) ubiquitin ligase complex9–20.”
From Defining molecular glues with a dual-nanobody cannabidiol sensor (2022) · cites this paper as [10]
In the citing paper
“As described before, in the presence of IMiDs, CRBN E3 ligase induces the proteasomal degradation of a set neo-substrates, such as IKZF1/3[13,39], CK1α[40] and GSPT1[15].”
From Development of MDM2 degraders based on ligands derived from Ugi reactions: Lessons and discoveries (2021) · cites this paper as [13]
In the citing paper
“This is further supported by the observations that PZ could selectively induce Bcl-xl but not Bcl-2 poly-ubiquitination and had no significant effect on the expression of the CRBN native substrate, glutamine synthetase (GS)36, and its neosubstrates recruited by thalidomide and its analogues including CK1α37, IKZF1, and IKZF3 (ref. 38) (Supplementary Fig. 1 f, g).”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [38]
In the citing paper
“In brief, IMiDs bind the E3 ligase cereblon (CRBN), thus complementing a surface patch that subsequently recruits a variety of C2H2 zinc finger transcription factors for ubiquitination and degradation.48−51”
From Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence (2023) · cites this paper as [50]
In the citing paper
“In brief, IMiDs were first shown to trigger CRBN-dependent proteasomal degradation of the C2H2-type zing-finger transcription factors Ikaros (IKZF1) and Aiolos (IKZF3).[46][47][48]”
From Chasing molecular glue degraders: screening approaches (2022) · cites this paper as [47]
In the citing paper
“The presence of a glutamine residue in their second zing-finger domain enables IMiD-induced degradation, 47 while the histidine residues in Helios (IKZF2) do not.”
From Chasing molecular glue degraders: screening approaches (2022) · cites this paper as [47]
In the citing paper
“thalidomide interacts with CRBN to form a novel surface, resulting in interactions with neosubstrates such as Ikaros (IKZF1) and Aiolos (IKZF3) and their ubiquitination and subsequent proteasomal degradation.20,21”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [20]
In the citing paper
“lenalidomide and pomalidomide induce CRBN-dependent ubiquitination and degradation of Ikaros and Aiolos, transcription factors required for the development of lymphoids and survival of multiple myeloma8–10.”
From Genome-wide screening reveals a role for subcellular localization of CRBN in the anti-myeloma activity of pomalidomide (2020) · cites this paper as [8]
In the citing paper
“Molecular glues, based on the serendipitous discovery that thalidomide and its analogues act as degrader molecules, constitute another important therapeutic class1–8.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [4]
In the citing paper
“These drugs co-opt CRBN to target IKAROS family zinc finger 1 (IKZF1) and IKZF3 for degradation3,4,24, and are now considered as pioneering examples of molecular glues.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [4]
In the citing paper
“CRBN appears to be emerging as a preferred E3 ligase for the first wave of TPD therapeutics in clinical trials.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [4]
In the citing paper
“Examples here include the approved IMiD class, which relies on CRBN to degrade IKZF1/IKZF3 (refs4,5) via a molecular glue mechanism”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [4]
In the citing paper
“thalidomide and its analogues do not inhibit the enzymatic activity of CRL4CRBN, but instead confer neomorphic activity on CRBN to mediate the selective ubiquitination and resultant proteasomal degradation of the transcription factors Ikaros family zinc finger protein 1 (IKZF1) and IKZF3 (Aiolos) in MM cells and T cells11–13.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [11]
In the citing paper
“In 2013, thalidomide analogues were discovered to exert their therapeutic effects by acting as a molecular glue to recruit disease-relevant neosubstrate proteins to an E3 ubiquitin ligase, resulting in neosubstrate ubiquitination and, ultimately, proteasomal degradation11–13.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [11]
In the citing paper
“given that proteasome inhibitors antagonize lenalidomide-induced protein degradation11,12,55.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [11]
In the citing paper
“Most known neosubstrate proteins have been identified through proteomic analyses of different cell lineages11,15,165,166.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [11]
In the citing paper
“Ebert's gourp and Kaelin Jr's group independently demonstrated that when lenalidomide binds to CRBN, a new function of CRBN is induced, namely, to ubiquitinate and degrade Ikaros (IKZF1) and Aiolos (IKZF3), which are transcription factors that are known to be responsible for the maturation of B cells [25,26].”
From Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs (2016) · cites this paper as [25]
In the citing paper
“CRBN was shown to bind the drug thalidomide in its substrate binding pocket, thereby creating a new surface to recruit other proteins for ubiquitination and degradation, such as the transcription factors Ikaros and Aiolos (IKZF1 and 3, respectively) or the kinase CK1α [70–72].”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [72]
In the citing paper
“The clinical efficacy of IMiDs is driven at least in part by their capacity to induce CRBN-mediated degradation of neo-substrates: cancer cells become resistant to the multiple myeloma IMiD drug lenalidomide upon mutation of a single amino acid in IKFZ3 that rescues this transcription factor from proteolytic degradation 7 ;”
From Targeted protein degradation: expanding the toolbox (2019) · cites this paper as [7]
In the citing paper
“cancer cells become resistant to the multiple myeloma IMiD drug lenalidomide upon mutation of a single amino acid in IKFZ3 that rescues this transcription factor from proteolytic degradation 7 ;”
From Targeted protein degradation: expanding the toolbox (2019) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rappsilber, J., Mann, M., & Ishihama, Y. (2007) · Nature Protocols · doi:10.1038/nprot.2007.261 · Cited by 4,641
RING Domain E3 Ubiquitin Ligases
Deshaies, R. J., & Joazeiro, C. A. P. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.101807.093809 · Cited by 2,679
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia
Mullighan, C. G., Goorha, S., Radtke, I., Miller, C. B., Coustan‐Smith, E., Dalton, J., Girtman, K., Mathew, S., Ma, J., Pounds, S. B., et al. (2007) · Nature · doi:10.1038/nature05690 · Cited by 1,777
Mechanism of auxin perception by the TIR1 ubiquitin ligase
Tan, X., Calderon-Villalobos, L. I. A., Sharon, M., Zheng, C., Robinson, C. V., Estelle, M., & Zheng, N. (2007) · Nature · doi:10.1038/nature05731 · Cited by 1,688
Sampaio, E. P., Sarno, E. N., Gallily, R., Cohn, Z. A., & Kaplan, G. (1991) · The Journal of Experimental Medicine · doi:10.1084/jem.173.3.699 · Cited by 1,191
The ikaros gene is required for the development of all lymphoid lineages
Georgopoulos, K., Bigby, M., Wang, J.-H., Molnar, A., Wu, P., Winandy, S., & Sharpe, A. (1994) · Cell · doi:10.1016/0092-8674(94)90407-3 · Cited by 985
A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC)
Ong, S., & Mann, M. (2006) · Nature Protocols · doi:10.1038/nprot.2006.427 · Cited by 917
Lopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A. K., Kang, J., Karasawa, S., Carmel, G., Jackson, P., Abbasian, M., et al. (2012) · Leukemia · doi:10.1038/leu.2012.119 · Cited by 814
Flagged first, then by citations
Cited by
Sorted by citations
Items 901–1,000 of 1,006
Aging-associated immune system changes in multiple myeloma: The dark side of the moon.
Visram, A., & Kourelis, T. (2021) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2021.100494 · Cited by 20
Mitochondrial cereblon functions as a Lon-type protease
Kataoka, K., Nakamura, C., Asahi, T., & Sawamura, N. (2016) · Scientific Reports · doi:10.1038/srep29986 · Cited by 18
Imaging dynamic cell signaling in vivo with new classes of fluorescent reporters
Shu, X. (2019) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.09.004 · Cited by 18
The “three body solution”: Structural insights into molecular glues
Tomlinson, A. C. A., Knox, J. E., Brunsveld, L., Ottmann, C., & Yano, J. K. (2025) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2025.103007 · Cited by 20
Trends in small-molecule probes for lipid droplets
Tu, Y., Zhang, W., Yan, J., Wang, M., Xu, B., & Xie, Y. (2025) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2025.118287 · Cited by 17
Molecular glues evolve from serendipity to rational design
Shrivastav, P., Singh, R., & Wiemer, A. J. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.10.013 · Cited by 21
Sculpting the proteome with small molecules
King, R. W., & Finley, D. J. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1671 · Cited by 17
Design and synthesis of new lenalidomide analogs via Suzuki cross‐coupling reaction
Xiao, D., Wang, Y., Wang, H., Zhou, Y., Li, J. X., Lu, W. P., & Jin, J. (2020) · Archiv der Pharmazie · doi:10.1002/ardp.201900376 · Cited by 17
Lian, Q., Gao, Y., Li, Q., He, X., Jiang, X., Pu, Z., & Xu, G. (2020) · The Protein Journal · doi:10.1007/s10930-020-09918-9 · Cited by 18
Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based Therapy
Walker, Z. J., Idler, B. M., Davis, L. N., Stevens, B. M., VanWyngarden, M. J., Ohlstrom, D. J., Bearrows, S. C., Hammes, A., Smith, C. A., Jordan, C. T., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2246 · Cited by 17
PLZF and its fusion proteins are pomalidomide-dependent CRBN neosubstrates
Shimizu, N., Asatsuma‐Okumura, T., Yamamoto, J., Yamaguchi, Y., Handa, H., & Ito, T. (2021) · Communications Biology · doi:10.1038/s42003-021-02801-y · Cited by 17
Recent advances in the pharmacological targeting of ubiquitin-regulating enzymes in cancer
Montagut, A. M., Armengol, M., Gorjón-de-Pablo, G., Estrada‐Tejedor, R., Borrell, J. I., & Roué, G. (2022) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2022.02.007 · Cited by 17
Sellin, M., Berg, S. A., Hagen, P. A., & Zhang, J. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101448 · Cited by 17
Visible-light promoted photocatalyst-free aerobic α-oxidation of tertiary amines to amides
Xie, X., Guo, X., Qiao, K., & Shi, L. (2022) · Organic & Biomolecular Chemistry · doi:10.1039/d2ob01565j · Cited by 17
HiBiT-SpyTag: A Minimal Tag for Covalent Protein Capture and Degrader Development
Tsang, T., Huerta, F., Liu, Y., Che, J., Metivier, R. J., Ferrao, S., Donovan, K. A., Jones, L. H., Zerfas, B. L., & Nowak, R. P. (2023) · ACS Chemical Biology · doi:10.1021/acschembio.3c00084 · Cited by 19
Proteolysis-targeting chimeras in biotherapeutics: Current trends and future applications
Li, Q., Zhou, L., Qin, S., Huang, Z., Li, B., Li, B., Yang, M., Nice, E. C., Zhu, H., & Huang, C. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115447 · Cited by 17
DCAF15 control of cohesin dynamics sustains acute myeloid leukemia
Grothusen, G. P., Chang, R., Cao, Z., Zhou, N., Mittal, M., Datta, A., Wulfridge, P., Beer, T., Wang, B., Zheng, N., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49882-x · Cited by 17
Zaman, S. U., Pagare, P. P., Huang, B., Rilee, G. J., Ma, Z., Zhang, Y., & Li, J. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107613 · Cited by 18
Fate induction in CD8 CAR T cells through asymmetric cell division
Lee, C. S., Chen, S., Berry, C. T., Kelly, A. R., Herman, P. J., Oh, S., O’Connor, R. S., Payne, A. S., & Ellebrecht, C. T. (2024) · Nature · doi:10.1038/s41586-024-07862-7 · Cited by 17
Yamashita, M., Ogawa, C., Zhang, B., Kobayashi, T., Nomura, A., Barker, C. S., Zou, C., Yamanaka, S., Hayashi, K., Shinkai, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54308-9 · Cited by 17
Yu, K., Phu, L., Varfolomeev, E. E., Bustos, D. J., Vucic, D., & Kirkpatrick, D. S. (2015) · Journal of Molecular Biology · doi:10.1016/j.jmb.2015.03.018 · Cited by 17
Ambrożak, A., Steinebach, C., Gardner, E. R., Beedie, S., Schnakenburg, G., Figg, W. D., & Gütschow, M. (2016) · ChemMedChem · doi:10.1002/cmdc.201600496 · Cited by 17
Tochigi, T., Miyamoto, T., Hatakeyama, K., Sakoda, T., Ishihara, D., Irifune, H., Shima, T., Kato, K., Maeda, T., Ito, T., et al. (2020) · Blood · doi:10.1182/blood.2019003749 · Cited by 19
Lagreca, I., Riva, G., Nasillo, V., Barozzi, P., Castelli, I., Basso, S., Bettelli, F., Giusti, D., Cuoghi, A., Bresciani, P., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095242 · Cited by 18
Wada, T., Asahi, T., & Sawamura, N. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.06.091 · Cited by 17
Misiewicz-Krzemińska, I., Corchete, L. A., Rojas, E. A., Martínez‐López, J., García‐Sánz, R., Oriol, A., Bladé, J., Lahuerta, J. J., Miguel, J. F. S., Mateos, M., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.181628 · Cited by 16
López-Relaño, J., Martín-Adrados, B., Real-Arévalo, I., Lozano-Bartolomé, J., Abós, B., Sánchez‐Ramón, S., Alonso, B., del Moral, M. G., & Martı́nez-Naves, E. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01328 · Cited by 16
Anti-inflammatory modulation of human myeloid-derived dendritic cell subsets by lenalidomide
Yamamoto, K., Kitawaki, T., Sugimoto, N., Fujita, H., Kawase, Y., Takaori‐Kondo, A., & Kadowaki, N. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.05.012 · Cited by 18
Unveiling the hidden interactome of CRBN molecular glues with chemoproteomicsPreprint
Baek, K., Metivier, R. J., Burman, S. S. R., Bushman, J. W., Yoon, H., Lumpkin, R. J., Abeja, D. M., Lakshminarayan, M., Yue, H., Ojeda, S., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.11.612438 · Cited by 17
Expanding the druggable zinc-finger proteome defines properties of drug-induced degradation
Slabicki, M. M., Park, J., Nowak, R. P., Burman, S. S. R., Pellman, J., Zou, C., Razumkov, H., Carreiro, J., Rastogi, S., Goldstein, A., et al. (2025) · Molecular Cell · doi:10.1016/j.molcel.2025.07.019 · Cited by 16
Self-citationGao, W., Huang, J., Deng, K., Lin, X., Long, X., Li, X., Huang, M., Wang, X., She, X., Liu, Q., et al. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101329 · Cited by 18
Self-citationRedirecting the Neo-Substrate Specificity of Cereblon-Targeting PROTACs to Helios
Verano, A. L., You, I., Donovan, K. A., Mageed, N., Yue, H., Nowak, R. P., Fischer, E. S., Wang, E. S., & Gray, N. S. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.2c00439 · Cited by 16
Saldarriaga, M. M., Darwiche, W., Jayabalan, D. S., Monge, J., Rosenbaum, C. A., Pearse, R. N., Niesvizky, R., & Bustoros, M. W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1020011 · Cited by 16
Li, S., Fu, J., Walker, C. J., Yang, J., Bhutani, D., Chakraborty, R., Mamillapalli, N., Mapara, M. Y., Landesman, Y., & Lentzsch, S. (2023) · Blood Advances · doi:10.1182/bloodadvances.2021006638 · Cited by 17
Nie, X., Zhao, Y. Q., Tang, H., Zhang, Z., Liao, J., Almodóvar‐Rivera, C. M., Sundaresan, R., Xie, H., Guo, L., Wang, B., et al. (2023) · ChemBioChem · doi:10.1002/cbic.202300685 · Cited by 17
Onyshchenko, K., Luo, R., Rao, X., Zhang, X., Gaedicke, S., Grosu, A., Firat, E., & Niedermann, G. (2024) · Theranostics · doi:10.7150/thno.88864 · Cited by 16
Livneh, I., Fabre, B., Goldhirsh, G., Chen, L., Zinger, A., Vainer, Y. S., Kaduri, M., Dahan, A., Ziv, T., Schroeder, A., et al. (2024) · Cell Death and Differentiation · doi:10.1038/s41418-024-01370-x · Cited by 16
Molecular glue degrader for tumor treatment
Hu, Y., Yan, Y., Wang, J., Hou, J., & Lin, Q. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1512666 · Cited by 17
Exploration of degrons and their ability to mediate targeted protein degradation
Harris, T. J., & Trader, D. J. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00787e · Cited by 15
Primed for degradation: How weak protein interactions enable molecular glue degraders
Hanzl, A., Inghelram, C., Schmitt, S., & Thomä, N. H. (2025) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2025.103052 · Cited by 17
Khan, A., Muzaffar, J., Murthy, H. S., Wingard, J. R., & Moreb, J. S. (2018) · Case Reports in Hematology · doi:10.1155/2018/9052314 · Cited by 16
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Lindner, S., Steinebach, C., Kehm, H., Mangold, M., Gütschow, M., & Krönke, J. (2019) · Journal of Visualized Experiments · doi:10.3791/59472 · Cited by 18
Self-citationCurrent and emerging immunotherapeutic approaches to the treatment of multiple myeloma
Swan, D., Lynch, K., Gurney, M. E., & O'Dwyer, M. E. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620719854171 · Cited by 16
Tsukamoto, T., Nakahata, S., Sato, R., Kanai, A., Nakano, M., Chinen, Y., Maegawa, S., Matsumura‐Kimoto, Y., Takimoto‐Shimomura, T., Mizuno, Y., et al. (2019) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20169 · Cited by 17
Tang, C., Zhang, Q., Wu, S., Tang, M., Liang, Q., Lin, X., Gao, Y., & Ge, Z. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03465-3 · Cited by 17
Interferon regulatory factor 4 as a therapeutic target in adult T-cell leukemia lymphoma
Rauch, D. A., Olson, S. L., Harding, J. C., Sundaramoorthi, H., Kim, Y., Zhou, T., MacLeod, A. R., Challen, G. A., & Ratner, L. (2020) · Retrovirology · doi:10.1186/s12977-020-00535-z · Cited by 17
Targeting pathogenic mechanisms in marginal zone lymphoma: from concepts and beyond
Lue, J. K., O’Connor, O. A., & Bertoni, F. (2020) · Annals of Lymphoma · doi:10.21037/aol-20-20 · Cited by 15
Sato, T., Ito, T., & Handa, H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.629326 · Cited by 17
Key regulators of sensitivity to immunomodulatory drugs in cancer treatment
Wang, S., Li, Z., & Gao, S. (2021) · Biomarker Research · doi:10.1186/s40364-021-00297-6 · Cited by 20
Zhou, L., & Xu, G. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167457 · Cited by 17
Emerging small molecule approaches to enhance the antimyeloma benefit of proteasome inhibitors
Driscoll, J. J., & Brailey, M. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9698-5 · Cited by 16
Primary central nervous system lymphoma: Novel precision therapies
Mondello, P., Mian, M., & Bertoni, F. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.06.009 · Cited by 15
Chen, Y., Cai, N., Lai, Y., Xu, W., Li, J., Huang, L., Huang, Y., Hu, M., Yang, H., & Chen, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01137 · Cited by 16
Ren, Y., Wang, M., Couto, S. S., Hansel, D. E., Miller, K., Lopez‐Girona, A., Bjorklund, C. C., Gandhi, A. K., Thakurta, A., Chopra, R., et al. (2015) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000246 · Cited by 16
A potent and selective ENL degrader suppresses oncogenic gene expression and leukemia progression
Xue, Z., Qin, L., Xuan, H., Luo, K., Huang, M., Xie, L., Su, Y., Xu, L., Harsh, J., Dale, B., et al. (2024) · Science Advances · doi:10.1126/sciadv.ado1432 · Cited by 15
Therapeutic targeting of chromatin alterations in leukemia and solid tumors
Perner, F., Berg, T., Sasca, D., Mersiowsky, S., Gadrey, J. Y., Thomas, J. M., Kühn, M. W. M., & Lübbert, M. (2025) · International Journal of Cancer · doi:10.1002/ijc.35389 · Cited by 16
Vasamsetti, S. B., Sadaf, S., Uddin, M. A., Shen, J., Johny, E., Mondal, A., Florentin, J., Lei, L., Mannan, A., Rao, K. M. K., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-69196-4 · Cited by 16
Park, S., Jo, S.-H., Kim, J.-H., Kim, S., Ha, J. D., Hwang, J. Y., Lee, M. Y., Kang, J. S., Han, T.-S., Park, S. G., et al. (2020) · Cancers · doi:10.3390/cancers12092541 · Cited by 15
Park, I., Phan, T. M., & Fang, J. (2021) · Cancers · doi:10.3390/cancers13205084 · Cited by 15
Discovery of potential novel CRBN modulators by virtual screening and bioassay
Xiong, F., Kong, L., Chen, L., Xue, M., Cao, F., Zhang, S., Li, H., Yan, H., Li, Y., & Zuo, Z. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114355 · Cited by 16
Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia
Eckardt, J., Stasik, S., Röllig, C., Petzold, A., Sauer, T., Scholl, S., Hochhaus, A., Crysandt, M. M., Brümmendorf, T. H., Naumann, R., et al. (2023) · Leukemia · doi:10.1038/s41375-023-02061-1 · Cited by 15
Regulation of eDHFR-tagged proteins with trimethoprim PROTACs
Etersque, J. M., Lee, I. K., Sharma, N., Xu, K., Ruff, A., Northrup, J. D., Sarkar, S., Nguyen, T., Lauman, R., Burslem, G. M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42820-3 · Cited by 17
Degron tagging for rapid protein degradation in mice
Hernández-Morán, B. A., Taylor, G. C. A., Lorente‐Macías, Á., & Wood, A. J. (2024) · Disease Models & Mechanisms · doi:10.1242/dmm.050613 · Cited by 14
Cullin-RING Ligase 4 in Cancer: Structure, Functions, and Mechanisms
Cheng, J., Bin, X., & Tang, Z. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189169 · Cited by 18
Another action of a thalidomide derivative
Ito, T., & Handa, H. (2015) · Nature · doi:10.1038/nature14628 · Cited by 15
Duan, W., Chen, S., Zhang, Y., Li, D., Wang, R., Chen, S., Li, J., Qiu, J. X., & Xu, G. (2015) · PROTEOMICS · doi:10.1002/pmic.201500356 · Cited by 15
Innovative Treatment Concepts for Cutaneous T-Cell Lymphoma Based on Microenvironment Modulation
Leuchte, K., Schlaak, M. S., Stadler, R., Theurich, S., & von Bergwelt‐Baildon, M. (2017) · Oncology Research and Treatment · doi:10.1159/000472257 · Cited by 15
Wang, A. C., Pham, H. T., Lipps, J., Brittain, S. M., Harrington, E. M., Wang, Y., King, F., Russ, C., Pan, X., Hoepfner, D., et al. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00656 · Cited by 15
Proteolysis-targeting Chimeras for Targeting Protein for Degradation
Qi, J., & Zhang, G. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0557 · Cited by 15
The Cul4‐DDB1‐WDR3/WDR6 Complex Binds SPAK and OSR1 Kinases in a Phosphorylation‐Dependent Manner
Dhiani, B. A., & Mehellou, Y. (2019) · ChemBioChem · doi:10.1002/cbic.201900454 · Cited by 15
Ganesan, S., Palani, H. K., Balasundaram, N., David, S., Devasia, A. J., George, B., & Mathews, V. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0431 · Cited by 15
Targeted Protein Degradation as a Promising Tool for Epigenetic Upregulation of Fetal Hemoglobin
Verheul, T. C. J., Trinh, V. T., Vázquez, O., & Philipsen, S. (2020) · ChemMedChem · doi:10.1002/cmdc.202000574 · Cited by 14
Rhabdomyosarcoma: How Advanced Molecular Methods Are Shaping the Diagnostic and Therapeutic Paradigm
Giannikopoulos, P., & Parham, D. M. (2021) · Pediatric and Developmental Pathology · doi:10.1177/10935266211013621 · Cited by 14
Harnessing the Immune System to Fight Multiple Myeloma
Krejcik, J., Barnkob, M. B., Nyvold, C. G., Larsen, T. S., Barington, T., & Abildgaard, N. (2021) · Cancers · doi:10.3390/cancers13184546 · Cited by 16
Roider, T., Brinkmann, B. J., Kim, V., Knoll, M., Kolb, C., Roessner, P. M., Bordas, M., Dreger, P., Müller‐Tidow, C., Huber, W. K., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005400 · Cited by 15
Catchet-MS identifies IKZF1-targeting thalidomide analogues as novel HIV-1 latency reversal agents
Ne, E., Crespo, R., Izquierdo-Lara, R. W., Rao, S., Koçer, S., Górska, A., van Staveren, T., Kan, T. W., van de Vijver, D. A. M. C., Dekkers, D. H. W., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac407 · Cited by 15
Bolomsky, A., Hübl, W., Spada, S., Müldür, E., Schlangen, K., Heintel, D., Rocci, A., Weißmann, A., Fritz, V., Willheim, M., et al. (2017) · American Journal of Hematology · doi:10.1002/ajh.24634 · Cited by 15
Proteomics-inspired precision medicine for treating and understanding multiple myeloma
Ho, M., Bianchi, G., & Anderson, K. C. (2020) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2020.1732205 · Cited by 16
A small molecule VHL molecular glue degrader for cysteine dioxygenase 1Preprint
Tutter, A. V., Buckley, D. L., Golosov, A. A., Ma, X., Shu, W., McKay, D. J., Darsigny, V., Dovala, D., Beckwith, R. E. J., Solomon, J. M., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.25.576086 · Cited by 16
Pan, Y., Wang, Y., & Gou, S. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108491 · Cited by 18
In-Cell Approach to Evaluate E3 Ligases for Use in Targeted Protein Degradation
Zheng, Y., Singh, A., Niu, Z., Marin, V. L., Young, J., Richardson, P. L., Hemshorn, M. L., Cooley, R. B., Karplus, P. A., Puvar, K., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c02741 · Cited by 16
Degradation of extracellular and membrane proteins in targeted therapy: Status quo and quo vadis
Li, Z., Ma, S., Zhang, S., Ma, Z., Du, L., & Li, M. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103716 · Cited by 14
Transcription factors in the development and treatment of immune disorders
Drinan, S. D., Bass, J. I. F., & Bass, J. I. F. (2023) · Transcription · doi:10.1080/21541264.2023.2294623 · Cited by 15
Harjunpää, H., Somermäki, R., Rubio, G. S., Fusciello, M., Feola, S., Faisal, I., Nieminen, A. I., Wang, L., Asens, M. L., Zhao, H., et al. (2024) · OncoImmunology · doi:10.1080/2162402x.2024.2369373 · Cited by 14
Zaman, S. U., Pagare, P. P., Ma, H., Hoyle, R. G., Zhang, Y., & Li, J. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00122b · Cited by 15
Gu, W., Liu, X., Shen, Y., Gong, Y.-T., Chen, Y., Lin, J., Lu, D., Zhang, L.-J., Chen, H., Jin, Y., et al. (2024) · Theranostics · doi:10.7150/thno.97662 · Cited by 14
Development of Ethyl-Hydrazide-Based Selective Histone Deacetylase 6 (HDAC6) PROTACs
Stopper, D., Honin, I., Feller, F., & Hansen, F. K. (2025) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5c00033 · Cited by 14
Richardson, P. G. G., Holstein, S. A., Schlossman, R. L., Anderson, K. C., Attal, M., & McCarthy, P. L. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1409207 · Cited by 14
Seeking Convergence and Cure with New Myeloma Therapies
Choudhry, P., Galligan, D. C., & Wiita, A. P. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.05.005 · Cited by 13
Inducing the Degradation of Disease-Related Proteins Using Heterobifunctional Molecules
Delport, A., & Hewer, R. (2019) · Molecules · doi:10.3390/molecules24183272 · Cited by 14
Cyclosporine enhances the sensitivity to lenalidomide in MDS/AML in vitro
He, X., Dou, A., Feng, S., Roman-Rivera, A., Hawkins, C., Lawley, L., Zhang, J., Wunderlich, M., Mizukawa, B. E., Halene, S., et al. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.05.001 · Cited by 18
Zou, J., Jones, R. J., Wang, H., Kuiatse, I., Shirazi, F., Manasanch, E. E., Lee, H. C., Sullivan, R., Fung, L. M., Richard, N., et al. (2020) · Journal of Molecular Medicine · doi:10.1007/s00109-020-01943-6 · Cited by 14
Alberge, J.-B., Magrangeas, F., Wagner, M., Denié, S., Guérin‐Charbonnel, C., Campion, L., Attal, M., Avet‐Loiseau, H., Carell, T., Moreau, P., et al. (2020) · Clinical Epigenetics · doi:10.1186/s13148-020-00953-y · Cited by 14
Cereblon: promise and challenges for combating human diseases
Kim, H. K., Seol, J. E., Ahn, S. W., Jeon, S., Park, C., & Han, J. (2021) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-021-02624-0 · Cited by 14
Endo, S., Amano, M., Nishimura, N., Ueno, N., Ueno, S., Yuki, H., Fujiwara, S., Wada, N. A., Hirata, S., Hata, H., et al. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.11.116 · Cited by 16
Chemical Methods to Knock Down the Amyloid Proteins
Gao, N., Chen, Y., Zhao, Y., & Li, Y. (2017) · Molecules · doi:10.3390/molecules22060916 · Cited by 14
Jian, Y., Gao, W., Geng, C., Zhou, H., Leng, Y., Li, Y., & Chen, W.-M. (2017) · Oncology Letters · doi:10.3892/ol.2017.6502 · Cited by 14
Kinoshita, S., Ri, M., Kanamori, T., Aoki, S., Yoshida, T., Narita, T., Totani, H., Ito, A., Kusumoto, S., Ishida, T., et al. (2018) · Oncology Letters · doi:10.3892/ol.2018.8501 · Cited by 14
The BET Bromodomain Inhibitor OTX015 Synergizes with Targeted Agents in Multiple Myeloma
Gu, J., Song, S., Han, H., Xu, H., Gao, F., Qian, C., Qiu, Y., Zhou, W., Zhuang, W., & Li, B.-Z. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00880 · Cited by 14
Identification of an allosteric site on the E3 ligase adapter cereblon
Dippon, V. N., Rizvi, Z., Choudhry, A. E., Chung, C.-W., Alkuraya, I. F., Xu, W., Tao, X. B., Jurewicz, A. J., Schneck, J. L., Chen, W., et al. (2026) · Nature · doi:10.1038/s41586-025-09994-w · Cited by 14
Metadata
- Authors
- Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., Ciarlo, C., Hartman, E., Munshi, N., Schenone, M., Schreiber, S. L., Carr, S. A., & Ebert, B. L.
- Affiliations
- Brigham and Women's Hospital (US)
- Broad Institute (US)
- Dana-Farber Cancer Institute (US)
- Corresponding author
- Ebert, Benjamin L.
- ORCID
- Venue
- Science
- Published
- 2014-01-17
- Volume
- 343
- Issue
- 6168
- Pages
- 301-305
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4077049
- OpenAlex
- W2015345028
- Semantic Scholar
- bf4fc60d821257f664ef758f219b75586ad0adaa
- Cited by
- 1,879
- References
- 31
- Citations by year
- 2026: 159 · 2025: 188 · 2024: 185 · 2023: 169 · 2022: 176 · 2021: 196 · 2020: 186 · 2019: 138 · 2018: 125 · 2017: 100 · 2016: 102 · 2015: 88 · 2014: 59
- FWCI
- 37.61
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Deutsche Forschungsgemeinschaft
- National Institutes of Health (5p01ca078378-15)
- National Heart, Lung, and Blood Institute (R01HL082945)
- National Human Genome Research Institute (RL1HG004671)
- National Cancer Institute (P01-CA078378, P50CA100707, P01CA108631, P01CA155258)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- lenalidomide, multiple myeloma, IKZF1, IKZF3, selective protein degradation, E3 ubiquitin ligase, ubiquitination, mechanism of action, IL-2 production, T cells, transcription factors
- MeSH terms
- Lenalidomide, Antineoplastic Agents, Humans, Interleukin-2, Multiple Myeloma, T-Lymphocytes, Thalidomide, Cell Line, Tumor, Ikaros Transcription Factor, Ubiquitination, HEK293 Cells, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
